Comparative Pharmacology
Head-to-head clinical analysis: ISOCLOR versus LEVOCETIRIZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ISOCLOR versus LEVOCETIRIZINE HYDROCHLORIDE.
ISOCLOR vs LEVOCETIRIZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Chlorpheniramine is an antihistamine (H1-receptor antagonist) that blocks the action of histamine, reducing allergy symptoms. Pseudoephedrine is a sympathomimetic amine that acts as a decongestant by stimulating alpha-adrenergic receptors, causing vasoconstriction in the nasal mucosa.
Levocetirizine is a selective peripheral histamine H1-receptor antagonist. It inhibits the effects of histamine at the H1 receptor, reducing allergic symptoms such as itching, sneezing, and rhinorrhea. It has lower affinity for central H1 receptors and anticholinergic properties compared to first-generation antihistamines.
Oral: 1 tablet (chlorpheniramine 4 mg / pseudoephedrine 60 mg) every 4-6 hours, not to exceed 4 tablets per 24 hours.
Oral, 5 mg once daily in the evening.
None Documented
None Documented
Approximately 2-4 hours in patients with normal renal function; prolonged to 8-12 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 7–8 hours in healthy adults; prolonged to 20–24 hours in renal impairment (CrCl <40 mL/min); clinically, stable levels require 2–3 days.
Primarily renal; approximately 60-70% of a dose excreted unchanged in urine within 24 hours. Biliary/fecal excretion accounts for <10%.
Approximately 85% renal excretion as unchanged drug via glomerular filtration and tubular secretion, 12.9% fecal excretion, <1% biliary.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine